No abstract available

No abstract available

No abstract available

[en] We describe a 52-year-old female patient who presented with a 9.5-cm fibrolamellar hepatocellular carcinoma (FL-HCC). The patient was initially unsuitable for surgical resection and therefore underwent transarterial chemoembolization followed by selective internal radiation therapy (SIRT) with Yttrium-90 to downsize the tumour. Following SIRT, the tumour decreased in volume from 350 to 20 cm³ allowing curative (R0) resection with an extended left hepatectomy and reconstruction of IVC. This is the first reported case of FL-HCC treated with SIRT in which, due to the good SIRT response, the patient was downsized to allow curative resection.

[en] Full text of publication follows. Aim: the aim of this study was to evaluate subjective and objective findings of patients with diffuse pigmented villonodular synovitis (DPVNS) of knee before and after treatment with Yttrium-90 (Y-90) radio-synovectomy. Materials and methods: between years 2005 and 2013, 23 patients, 15 female and 8 male, who had adjuvant radio-synovectomy after arthroscopic surgery were included to our study. 5 mCi of Y-90 radiocolloid was administered under local anesthesia at least 6 weeks after arthroscopic surgery. The patients were reevaluated 6 months after radio-synovectomy. All the patients were assigned a Lysholm knee score prior to surgery, prior to radio-synovectomy and 6 months after radio-synovectomy. Lysholm score was calculated according to patients' pain, swelling, instability, locking, limping, support, climbing the stairs, squatting and the highest evaluation score was 100. In addition modified Marshall scoring system was calculated according to objective and subjective findings of the patients prior to surgery and six months after radio-synovectomy. The highest evaluation score was 30 in modified Marshall scoring system where 19 points were provided by objective findings and 11 points were provided by subjective findings. Scores higher than 26 were defined as very good, between 21-25 was good, between 16-20 was medium, and values less than 16 points are considered to be poor. The obtained points using scoring systems were evaluated statistically. Results: the mean age was (31.7 ± 13.2) years. The average time period between the operation and radio-synovectomy was (12.8 ± 8.14) weeks. The calculated Lysholm scores prior to surgery, prior to radio-synovectomy and 6 months after radio-synovectomy were (38.8 ± 4.1), (60.0 ± 4.4) and (82.9 ± 6.5), respectively (p <0.001). Modified Marshall scores prior to surgery, and 6 months after radio-synovectomy, was (12.4 ± 2.7) and (25.5 ± 3.1) respectively (p <0.001). Conclusion: we conclude that Y-90 therapy in patients with DPVNS of knee is efficient in treatment of objective and subjective symptoms. In addition both scoring systems are reliable predictors of effectiveness of the Y-90 therapy. (authors)

[en] Nivolumab has recently received approval by the Food and Drug Administration for treatment of advanced hepatocellular carcinoma (HCC) in patients previously treated with sorafenib. Nivolumabs’ overall response rate of 20% (El-Khoueiry et al. in Lancet 389:2492–2502, 2017) is a step forward for these patients, but there is significant room for improvement. We describe a case of combining Y-90 radioembolization with nivolumab for treatment of angioinvasive HCC, which successfully bridged patient to partial hepatectomy. Surgical pathology showed negative margins with complete pathological response. With the introduction of immunotherapy for HCC, combining Y-90 radioembolization with immunotherapy may enhance the anti-tumoral immune response of checkpoint inhibitors.

[en] Abstract only

[en] The full text of the publication follows. Because of radiation of high beta-energy and short half-life time, ⁹⁰Y is widely used for the labelling of targeted molecules that are used in the treatment of cancer. DOTATATE is an analogous of somatostatin, the naturally occurring peptide with diverse functions. The role of DOTATATE is to introduce radioactive particle in solid tumor. The aim of this study was to explore possible competition of iron ions with yttrium ions during the labelling process of DOTATATE. The importance of this research can be seen in the fact that during the process of labelling, syringes with steel needles were used. Series of different concentrations of iron were prepared. The molar ratios of DOTATATE/Fe were: 2:1, 5:1 and 10:1. After that, the standard procedure of labelling DOTATATE with yttrium was performed using 925 MBq of ⁹⁰Y as ⁹⁰Y chloride solution. The control of radioactivity was carried out on CAPINTEC CRC 15-BETA dose calibrator that had been previously calibrated for ⁹⁰Y. The control of radiochemical purity of the radiolabelled peptide was carried out by HPLC, ITLC and by extraction chromatography Sep-Pak columns. Additionally, the concentration of contaminating Fe was confirmed by ICP-optical emission spectrometry. Obtained results showed that iron contamination of the solution significantly reduces the yield during the labelling of DOTATATE with ⁹⁰Y as ions compete with iron ions in yttrium labelling. (authors)

[en] The purpose of the study was to evaluate the success rate of synoviorthesis in 273 patients with painful and swollen large joints (jts), up to nine years after the intraarticular application of Y-90. 402 knees, and 64 shoulders or ankles were treated. Rheumatoid arthritis was present in 449 jts, 64 jts were afflicted by osteoarthritis or other rheumatic diseases. 185 MBq were applied in knees and shoulders and 111 MBq of Y-90 in ankles. The effect of therapy was evaluated considering the degree of morning stiffness, pain and swelling. The effect of therapy was moderate in 42.5%%, good in 30.6% and very good in 14.9%% of jts. There was no improvement noted in 11.8%% of jts. The duration of improvement was in average 2.8 years. In 11 %% of pts the improvement lasted 6-9 years after therapy. Transient side effects were noted in 5.6%% of pts, pain and swelling were most frequent. Malignant diseases developed during the follow-up period (less than 4 years) in three pts. We conclude that radioisotopic synoviorthesis mostly has a satisfactory effect with mean duration of 2.8 years. Serious side effects were rare. (author)

[en] Short communication